# Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Source: https://onco.cc/trials/nct04562389/  
OnCo record `nct04562389` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Selinexor and Ruxolitinib in myeloproliferative neoplasms, run by Karyopharm Therapeutics Inc, active and no longer recruiting.

## Summary

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis is a phase 3 interventional study registered as NCT04562389 by Karyopharm Therapeutics Inc, with 353 participants enrolled, started 2021-03-11 and due to reach its primary completion in 2026-02-20. Interventions recorded: Selinexor and Ruxolitinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04562389
- Phase: 3
- Setting: A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis
- Sponsor: Karyopharm Therapeutics Inc
- Enrolled: 353

## Sources

- ClinicalTrials.gov NCT04562389: https://clinicaltrials.gov/study/NCT04562389

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/), [Selinexor](https://onco.cc/drugs/selinexor/)
- companies: [Karyopharm Therapeutics](https://onco.cc/companies/karyopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct04562389.json